More Access and Evidence Articles

Access and Evidence

When the Machines Take Over

Deirdre Coleman, (May 30, 2017)

How technology is making the world's health data useful
Access and Evidence

What the FDA Really Thinks About Real-World Evidence

Deirdre Coleman, (May 19, 2017)

Real-world evidence is a critical issue for the FDA, but we must work together to ensure it meets the highest possible standards, says former FDA Commissioner, Robert Califf
Access and Evidence

Towards A New Era in Oncology

Danielle Barron, (May 19, 2017)

Companies must demonstrate meaningful clinical outcomes to guarantee access to their medicines, says Patricia Andrews, the new CEO of Boston Biomedical
Access and Evidence

Will 2017 See a Biosimilar Bonanza in the US?

Deirdre Coleman, (Apr 19, 2017)

How biosimilars are overcoming the barriers to market access in the US
Access and Evidence

Arbiter of Value

Deirdre Coleman, (Mar 17, 2017)

ICER has the laudable mission of being an independent, trusted source of value assessment for medicines. We spoke to Chief Scientific Officer, Dan Ollendorf, about controversy, criticism and the power of collaboration.
Access and Evidence

Oncology: Solving the Value Conundrum

Danielle Barron, (Mar 14, 2017)

Value-based contracts represent a genuine opportunity to build resilient relationships with payers - if pharma can overcome the practical issues
Access and Evidence

Working in Sync

Deirdre Coleman, (Mar 7, 2017)

Maximizing reimbursement in a challenging pricing environment requires market access and pricing teams to work in concert
Access and Evidence

Getting Social in the Real World

Danielle Barron, (Mar 6, 2017)

The growing role of social media in gathering real-world data
Access and Evidence

All Over the Map

Dr Nicola Davies, (Mar 3, 2017)

How can pharma meet the needs of payers in such a fragmented landscape?
Access and Evidence

R&D Gets Real with Real-World Evidence

Danielle Barron, (Mar 1, 2017)

Bringing RWE into the earlier stages of R&D needs a collective effort from companies, regulators and other stakeholders

Pages